Novavax, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Charles Jacobs
- Full Time Employees
- 952
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21 Firstfield Road Gaithersburg MD United States of America 20878
- IPO Date
- Dec 5, 1995
- CIK
- 0001000694
- Website
- novavax.com
- Similar Companies
- Business
- Novavax, Inc., a biotechnology enterprise, dedicates itself to the research, advancement, and market introduction of vaccines aimed at preventing significant infectious illnesses. The company's lead commercial offering, Nuvaxovid, is a protein-based COVID-19 vaccine, which has secured full regulatory approval in the U.S. for adults aged 65 and older, as well as individuals 12 to 64 years old with specific elevated risk factors, providing a non-mRNA alternative. Its pipeline relies on a proprietary recombinant nanoparticle technology and the Matrix-M adjuvant. Important investigational programs feature a COVID-19-Influenza Combination vaccine and a standalone seasonal influenza vaccine, both advancing through Phase 3 clinical trials. Furthermore, a respiratory syncytial virus (RSV) F protein nanoparticle vaccine candidate remains under development. The company actively engages in strategic alliances, including a significant collaboration with Sanofi for the co-commercialization of Nuvaxovid and joint development of combination vaccines, and a partnership with Takeda for its COVID-19 vaccine in Japan. Novavax, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb
Hantavirus cases spark surge in pharma and biotech stocks — here's why
What's Going On With Novavax Stock On Friday?
Novavax to Participate in BofA Securities 2026 Health Care Conference
NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum
Why Novavax Stock Is Trading Higher On Wednesday?
Novavax, Inc. (NVAX) Q1 2026 Earnings Call Transcript
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Novavax to Report First Quarter 2026 Financial Results on May 6, 2026
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know